Merck Reports P-III Trial (STELLAR) Results of Sotatercept for Pulmonary Arterial Hypertension
Shots:
- The P-III trial (STELLAR) evaluating sotatercept + stable background therapy in 323 adult patients, showed an improvement in exercise capacity, increasing 6MWD by 40.8 meters from baseline @24wk.
- Multi-component improvement @24wk. i.e., (improvement in 6MWD, NT-proBNP level & WHO FC or maintenance of WHO FC II) was 38.9% vs 10.1%, improved in WHO FC (29.4% vs 13.8%), 84% reduction in risk of clinical worsening or death with a median follow-up of 32.7wks.
- Patients achieved or maintained a low French risk score (39.5% vs 18.2%), PROs, avg. scores for physical impacts & cardiopulmonary symptoms were reduced, TEAEs (90.8% vs 91.9%), sev. TEAEs (12.9% vs 18.1%). The results were presented at ACC’s 72nd annual scientific session with WCC & published in the NEJM
Ref: Merck | Image: Merck
Related Post:- Merck Reports P-III (STELLAR) Trial Results of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
